Citigroup Notifies That Stabilization Measures Have Been Undertaken in Calliditas Therapeutics' ADSs Traded on The Nasdaq Global Select Market
Citigroup Global Markets has announced stabilization measures for Calliditas Therapeutics' American Depositary Shares (ADSs) listed on Nasdaq. This follows the company's recent U.S. Offering through a capital increase of ADSs, priced at USD 19.50. Stabilization transactions aim to support market prices within the offering period, which ends July 4, 2020. Additionally, an over-allotment option allows Citigroup to sell up to 692,306 ADSs, representing 15% of shares in the Global Offering. No stabilization will occur on Nasdaq Stockholm.
- Stabilization measures undertaken to support market price.
- Over-allotment option to sell additional 692,306 ADSs potentially enhances liquidity.
- Potential market uncertainty if stabilization is not sufficient.
- No assurance that Citigroup will undertake stabilization actions.
STOCKHOLM, June 25, 2020 /PRNewswire/ -- Citigroup Global Markets Inc. ("Citigroup"), in its capacity as Joint Global Coordinator, notifies that stabilization measures have been undertaken in Calliditas Therapeutics AB's ("Calliditas" or the "Company") American Depositary Shares ("ADSs"), traded on The Nasdaq Global Select Market.
As announced by the Company in connection with the initial public offering on The Nasdaq Global Select Market, by way of a capital increase of new common shares in the form of ADSs, each representing two (2) underlying new common shares of Calliditas, (the "U.S. Offering"), and a concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United States (together with the U.S. Offering, the "Global Offering"), Citigroup may, acting as Joint Global Coordinator and stabilization manager, carry out transactions aimed at supporting the market price of the ADSs at levels above those which might otherwise prevail in the market.
Stabilization transactions may be undertaken on The Nasdaq Global Select Market, in the over-thecounter market or otherwise, at any time during the period starting on the day of pricing of the ADSs on The Nasdaq Global Select Market, 4 June 2020, and ending no later than 30 calendar days thereafter. Citigroup is, however, not required to undertake any stabilization and there is no assurance that stabilization will be undertaken. Stabilization, if undertaken, may be discontinued at any time without prior notice. In no event will transactions be effected at a price higher than the price in the U.S. Offering, i.e. USD 19.50. No stabilization measures have taken or will take place on Nasdaq Stockholm.
The board of directors of the Company have granted the Joint Global Coordinators an over-allotment option which may be utilized in whole or in part for 30 days from the date of pricing of the Company's ADSs, to sell up to 692,306 ADS corresponding to up to 15 percent of the total number of common shares in the Global Offering, at a price corresponding to the price in the U.S. Offering, i.e. USD 19.50 per ADS, to cover any over-allotment in connection with the Global Offering.
Citigroup has, in its capacity as stabilization manager, notified in accordance with article 5(4) in the Market Abuse Regulation 596/2014 that stabilization measures have been undertaken, in accordance with Reg M, Rule 104 of the U.S. Securities Act of 1933, as amended, on The Nasdaq Global Select Market as specified below. Undertaken stabilization measures were also announced on 12 June 2020. The contact person at Citigroup is Dean Poniros (tel: +1 212 723 6137, e-mail: dean.poniros@citi.com).
Stabilization information: | |
Issuer: | Calliditas Therapeutics AB (publ) |
Securities: | American Depositary Shares (ISIN: US13124Q1067) |
Offering size: | 692,306 ADSs, representing 1,384,612 underlying common shares |
Offer price: | USD 19.50 |
Ticker: | CALT |
Stabilization manager: | Citigroup Global Markets Inc. |
Stabilization transactions: | ||||||
Date | Quantity, ADS | Price (highest) | Price (lowest) | Price (volume weighted average) | Currency | Trading venue |
2020-06-15 | 75 | 19.25 | 19.25 | 19.25 | USD | The Nasdaq Global Select Market |
2020-06-16 | 600 | 19.25 | 19.25 | 19.25 | USD | The Nasdaq Global Select Market |
2020-06-18 | 4,666 | 19.15 | 19.15 | 19.15 | USD | The Nasdaq Global Select Market |
2020-06-19 | 4,913 | 19.00 | 19.00 | 19.00 | USD | The Nasdaq Global Select Market |
This information is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out below, at 10:45 pm CEST on 24 June 2020.
About Calliditas
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and The Nasdaq Global Select Market (ticker: CALT).
For further information, please contact:
Renée Aguiar-Lucander, CEO at Calliditas
E-mail: renee.lucander@calliditas.com
Telephone: +46 722 52 10 06
Mikael Widell, Head of Communications at Calliditas
E-mail: mikael.widell@calliditas.com
Telephone: +46 703 11 99 60
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
!["Cision"]("https://c212.net/c/img/favicon.png?sn=IO45967&sd=2020-06-24" "\"Cision\"")
View original content:http://www.prnewswire.com/news-releases/citigroup-notifies-that-stabilization-measures-have-been-undertaken-in-calliditas-therapeutics-adss-traded-on-the-nasdaq-global-select-market-301083385.html
SOURCE Calliditas Therapeutics
FAQ
What stabilization measures are being implemented for CALT?
What is the offering price for Calliditas Therapeutics ADSs?
What is the total number of ADSs involved in the offering?
When does the stabilization period for CALT end?
Who is the stabilization manager for CALT?
